The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately ...

BL-M11D1, a CD33-binding antibody-drug conjugate, is being evaluated for the treatment of patients with acute myeloid ...

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...

Panelists discuss how the introduction of adjuvant immunotherapy has influenced their first-line treatment decisions for ...

Joshua K. Sabari, MD, discusses how, despite the relatively small numbers of CRs and PRs in the DeLLphi-301 trial, the DOR to ...

Saeed Sadeghi, MD, reviews real-world data on luspatercept, discussing treatment patterns and outcomes, including transfusion burden, hemoglobin increase, and other key baseline data that may differ ...

Joshua K. Sabari, MD, discusses how the ORR of 32% to 40% observed in the DeLLphi-301 clinical trial among participants receiving tarlatamab is clinically meaningful, particularly given that these ...

For Breast Cancer Awareness Month, Deborah Toppmeyer, MD, emphasizes the crucial role of early breast cancer detection.

Cologuard Plus test receives FDA approval, understanding genomic profiling leads to advanced personalized care in breast cancer, and a new CAR T therapy is making waves in multiple myeloma.

John Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the ...